TRESBIEN (OGSG 2101) Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC

Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type

進行胃癌一次治療におけるSP対XPの無作為化試験のメタ解析

Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy OGSG1201

Stage II/III大腸癌根治切除後の補助化学療法中または治療後に再発したRAS野生型かつBRAF V600E変異型の早期再発大腸癌患者に対するエンコラフェニブ+ビニメチニブ+セツキシマブ療法の有効性と安全性を探索する第II相試験 (TRESBIEN/OGSG2101)

フッ化ピリミジン系薬剤とプラチナ系薬剤との併用療法に不応となった進行・再発食道癌に対するドセタキセル単独療法とパクリタキセル単独療法のランダム化比較第Ⅱ相試験（OGSG1201）

TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease